|
Q1 FY2027
As of Sep 30, 2026
|
Q4 FY2026
As of Jun 30, 2026
|
Q3 FY2026
As of Mar 31, 2026
|
Q2 FY2026
As of Dec 31, 2025
|
Q1 FY2026
As of Sep 30, 2025
|
Q4 FY2025
As of Jun 30, 2025
|
Q3 FY2025
As of Mar 31, 2025
|
Q2 FY2025
As of Dec 31, 2024
|
Q1 FY2025
As of Sep 30, 2024
|
Q4 FY2024
As of Jun 30, 2024
|
Q3 FY2024
As of Mar 31, 2024
|
Q2 FY2024
As of Dec 31, 2023
|
Q1 FY2024
As of Sep 30, 2023
|
Q4 FY2023
As of Jun 30, 2023
|
Q3 FY2023
As of Mar 31, 2023
|
Q2 FY2023
As of Dec 31, 2022
|
Q1 FY2023
As of Sep 30, 2022
|
Q4 FY2022
As of Jun 30, 2022
|
Q3 FY2022
As of Mar 31, 2022
|
Q2 FY2022
As of Dec 31, 2021
|
|
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ASSETS | ||||||||||||||||||||
| CURRENT ASSETS: | ||||||||||||||||||||
| Cash and cash equivalents | ||||||||||||||||||||
| Trade receivables - less allowances: September 30, 2026 and June 30, 2026, $2,040 | ||||||||||||||||||||
| Inventories | ||||||||||||||||||||
| Other | ||||||||||||||||||||
| Assets held for sale | ||||||||||||||||||||
| Total current assets | ||||||||||||||||||||
| NONCURRENT ASSETS: | ||||||||||||||||||||
| Property, plant and equipment, net | ||||||||||||||||||||
| Operating lease right-of-use assets | ||||||||||||||||||||
| Deferred income taxes | ||||||||||||||||||||
| Other assets | ||||||||||||||||||||
| TOTAL ASSETS | ||||||||||||||||||||
| LIABILITIES AND SHAREHOLDERS' EQUITY | ||||||||||||||||||||
| CURRENT LIABILITIES: | ||||||||||||||||||||
| Accounts payable - trade | ||||||||||||||||||||
| Current portion of operating lease liabilities | ||||||||||||||||||||
| Accrued liabilities: | ||||||||||||||||||||
| Payroll and related items | ||||||||||||||||||||
| Insurance | ||||||||||||||||||||
| Restructuring costs | ||||||||||||||||||||
| Sales and advertising related items | ||||||||||||||||||||
| Other | ||||||||||||||||||||
| Total current liabilities | ||||||||||||||||||||
| LONG-TERM LIABILITIES: | ||||||||||||||||||||
| Operating lease liabilities, less current maturities | ||||||||||||||||||||
| Line of credit | ||||||||||||||||||||
| Other liabilities | ||||||||||||||||||||
| Total liabilities | ||||||||||||||||||||
| SHAREHOLDERS' EQUITY: | ||||||||||||||||||||
| Common stock - $1 par value; authorized 15,000 shares; 8,716 shares issued and 4,166 outstanding as of September 30, 2026; 8,629 shares issued and 4,107 outstanding as of June 30, 2026 | ||||||||||||||||||||
| Additional paid-in capital | ||||||||||||||||||||
| Treasury stock, at cost; 4,550 shares as of September 30, 2026, and 4,522 shares as of June 30, 2026 | ||||||||||||||||||||
| Retained earnings | ||||||||||||||||||||
| Total shareholders' equity | ||||||||||||||||||||
| TOTAL LIABILITIES AND SHAREHOLDERS' EQUITY | ||||||||||||||||||||
Loading...
